Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 47.60
Bid: 46.80
Ask: 49.70
Change: -3.25 (-6.31%)
Spread: 2.90 (6.197%)
Open: 51.00
High: 51.00
Low: 47.60
Prev. Close: 51.50
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DHSC application for summary judgment dismissed

1 May 2024 07:00

RNS Number : 7004M
Novacyt S.A.
01 May 2024
 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

DHSC application for summary judgment dismissed

 

Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.

 

The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.

 

 

 

Contacts

 

Novacyt SA

https://novacyt.com/investors

Lyn Rees, Chief Executive Officer

 Via Walbrook PR

Steve Gibson, Chief Financial Officer 

 

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Paul McManus /

Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com

+44 (0)7796 794 663 / +44 (0)7980 541 893

 +44 (0)7867 984 082 / +44 (0)7407 804 654

 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical

Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

· Precision Medicine: DPYD genotyping assay

· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

 

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

· Ranger® Technology: automated DNA sample preparation and target enrichment technology

MyGo: real-time quantitative PCR (qPCR) instruments

 

Research Use Only

Range of services for the research industry:

· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAXLEDDNLEFA
Date   Source Headline
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
3rd Jul 202312:00 pmRNSLiquidity Agreement and Total Voting Rights
3rd Jul 20237:01 amRNSRecommended cash offer for Yourgene Health plc
15th Jun 20234:00 pmRNSNotice of rescheduled AGM
12th Jun 20237:00 amRNSReminder to shareholders re. AGM voting
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Sep 202212:00 pmRNSLiquidity Agreement and Total Voting Rights
4th Aug 20227:00 amRNSLaunch of first fully lyophilised PROmate® assays
1st Aug 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jul 20227:00 amRNSLaunch of research-use-only adenovirus F41 assay
20th Jul 20223:00 pmRNSResults of AGM
15th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSApproval of exsig™ COVID-19 Direct test in the UK
7th Jul 20223:00 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSTrading update and progress against strategy
5th Jul 202211:45 amRNSHoldings in Company
1st Jul 202212:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jun 20227:00 amRNSLaunch of monkeypox assay
21st Jun 20222:00 pmRNSNotice of rescheduled AGM
16th Jun 20227:00 amRNSDHSC dispute update
13th Jun 20227:00 amRNSAGM Voting
1st Jun 20221:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Jun 20227:00 amRNSCTDA approval and CE mark
1st Jun 20227:00 amRNSPublication of Annual Report and AGM voting
13th May 20227:00 amRNSNotice of Annual General Meeting
3rd May 202212:21 pmRNSLiquidity Agreement Update and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.